SCHEMBL486062

SCHEMBL486062

C=CCOc1c(CC=C)cccc1C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
CYP3A4 P08684 1/20 0.41
LIG1 P18858 1/20 0.41
ALDH1A1 P00352 3/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HPGD P15428 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HSP90AA1 P07900 1/20 0.40
HTT P42858 1/20 0.40
PARP1 P09874 2/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CXCR5 P32302 2/20 0.38
TLR4 O00206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299375 0.87 SMN1; SMN2 (0.46) KDM4ECYP3A4LIG1ALDH1A1TSHR
SCHEMBL24440337 0.84 KDM4E (0.43) KDM4EALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL1520942 0.81 CXCR5 (0.55) KDM4ECYP3A4LIG1ALDH1A1TSHR
SCHEMBL11602955 0.81 GABRA1 (0.47) KDM4EALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL6365179 0.79 SCN1A (0.38) KDM4ELIG1ALDH1A1POLBSMN1; SMN2
SCHEMBL83923 0.77 KDM4E (0.50) KDM4ECYP3A4ALDH1A1TSHRHSD17B10
SCHEMBL7870129 0.76 GABRA1 (0.44) KDM4ECYP3A4ALDH1A1TSHRHSD17B10
SCHEMBL8824319 0.76 GABRA1 (0.44) KDM4ECYP3A4ALDH1A1TSHRHSD17B10
SCHEMBL12611132 0.76 GABRA1 (0.58) KDM4EALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL27420156 0.76 GABRA1 (0.44) KDM4EALDH1A1TSHRHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411388-A2 PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES Elan Pharmaceuticals Inc. (US) 2012-02-01 EP disclosed
WO-2010111418-A2 PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2010-09-30 WO disclosed